46 results about "Thienopyridine" patented technology

The present invention discloses thiopheno pyridine substituted acetyl hyarazine derivative compound as shown in expression I and its pharmaceutically acceptable salt, medicine composition with the compound as effective component, and their application as platelet aggregation resisting medicine, especially as medicine for preventing and treating platelet aggregation caused coronary artery syndromes, myocardial infarction, myocardial ischemia and other cardiac and cerebral vascular diseases.

A formulation of a compound of formula (I) process of manufacture and methods of using it are disclosed.

The present invention relates to selective allosteric potentiators of the Formula (I):

or pharmaceutically acceptable salts thereof, for the treatment of disorders associated with M₄ muscarinic receptors.

The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from thienopyrimidine and thienopyridine compounds Formula I′ and Formula II′:

where R₁, R₃, B, Z, Q, p, q and X are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

The invention pertains to the technical field of medicaments for preventing platelet aggregation and provides an oxime derivative which contains thienopyridine and has a structure as shown in the general formula (I), and pharmaceutically acceptable salt thereof, wherein, m equals to 1 and 2 and n equals to 0 and 1; R <1 >, R <2> and R <3> collectively or individually refer to hydrogen, C1-C6 straight-chain or branched-chain alkyl, C3-C6 naphthenic base, halogen, hydroxyl, carboxyl, amino, amido, cyano, nitryl, C1-C4 alkoxy, substituted phenyl and substituted heterocyclic radical; and R<4> refers to hydrogen, C1-C4 straight-chain or branched-chain alkyl as defined in the Instruction in details. In addition, the invention also relates to a preparation method of the compounds and discloses medicament combinations of which the compound or the pharmaceutically acceptable salt of the compound is taken as active ingredient and the application of such medicament combinations as drugs for preventing platelet aggregation.

The invention is directed to thienopyrimidines and thienopyridines compounds of Formula I and Formula II:

where R₁, R₃, B, Z, Q, p, q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3, the use of such compounds to reduce or inhibit kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

The invention, belonging to the field of pharmaceutical chemicals, relates to a Thienopyridine alpha-amino benzylphosphonate, a preparation method and an application thereof. concretely, the invention relates to a compound of formula I, its medicinal salt, racemate, stereoisomer, or solvate, wherein each substituent is defined in the specification. The invention further relates to a pharmaceutical composition of the compound. The compound of the invention can effectively resist platelet aggregation and/or protect vascular endothelial cells.

This application relates to novel fused tricyclic thienopyridines of Formulas I and II, which useful for treating Hepatitis B infection and other diseases. This application also relates to pharmaceutical compositions comprising thienopyridines and to the use of such compositions to treat Hepatitis B and other diseases.

The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.

The invention discloses a new thienopyridine compound (shown in a formula I) and a salt thereof. Experiments prove that the new thienopyridine compound can be used for treating and preventing ischemic disease and improving sleep. When R2 represents H, the new thienopyridine compound can react with organic acids (such as phosphoric acid, hydrogen nitrate and sulfuric acid) and organic acids (such as methanoic acid, acetic acid, propanoic acid, oxalic acid, malonic acid, aminoacetic acid, valine, maleic acid, fumaric acid and succinic acid) to generate ester, and further react with acid or basic group to generate a salt. The salt also has the functions of treating and preventing ischemic disease and improving sleep.

Thienopyridine compounds which are potassium channel inhibitors are described. Pharmaceutical compositions comprising the compounds and their use in the treatment or prevention of cancer, arrhythmias, autoimmune diseases and inflammatory diseases, including gastric cancer, atrial fibrillation, type-2 diabetes mellitus, rheumatoid arthritis, type-1 diabetes, inflammatory bowel disorder and demyelinating disorders such as multiple sclerosis are also disclosed.

The invention relates to novel 5-cyano-thienopyridines of the formula (I) where R1, R2, and R3 have the meanings designated in Claim 1. Said 5-cyano-thienopyridines are inhibitors of TGF-beta receptor kinase and may be used, among other things, for the treatment of tumors.

The compound of the present invention possesses excellent gonadotropin-releasing hormone antagonizing activity, and is useful for preventing or treating sex hormone-dependent diseases, e,g., sex hormone-dependent cancers (e.g., prostatic cancer, uterine cancer, breast cancer, pituitary tumor), prostatic hypertrophy, hysteromyoma, endometriosis, precocious puberty, amenorrhea sydrome, multilocular ovary sydrome, pimples etc, or as a pregnancy regulator (e.g., contraceptive), infertility remedy or menstruation regulator.

The invention provides a reagent card for detecting the therapeutic effect of thienopyridine antiplatelet drugs and an application method and application of the reagent card. The reagent card comprises four detection channels which are sequentially arranged in parallel and are independent of one another, the detection channel I contains channel I detection reagent, and the channel I detection reagent contains a lyophilized agent, wherein the lyophilized agent is obtained by firmly bonding activated dye microspheres with receptor ligand of blood platelets GpIIb/IIIa through amido bonds, then adding blood coagulation factors, and conducting freeze-drying; the detection channel II contains channel II detection reagent, and the channel II detection reagent contains a lyophilized agent serving as a blood platelet maximum activating agent; the detection channel III contains no detection reagent, the detection channel IV contains channel IV detection reagent, and the channel IV detection reagent contains a lyophilized agent serving as a blood platelet P2Y12 receptor activating agent and P2Y1 receptor antagonist. By means of the reagent card, the therapeutic effect of thienopyridine antiplatelet drugs can be detected easily, fast, conveniently and accurately.

The invention provides organic dye and the application of the organic dye in a dye-sensitized solar cell, belonging to the field of organic dye. The organic dye takes N-biphenyl substituted di-thienopyridine as a conjugate unit, and takes a thienopyridine structure unit as an electron-rich structure unit, so that the dye is better in optical absorptivity; and a N atom is connected with a long alkyl chain, so that the gathering of the dye can be preferably reduced, and the photovoltage of a device can be improved. The organic dye provided by the invention is simple in synthesis process, low in raw material cost, high in reaction yield, and easy to purify. According to the dye-sensitized solar cell prepared by the organic dye provided by the invention, the high voltage of 960 millivolts and the short-circuit current density of 13.53 milliamperes/ square centimeter can be achieved, and the power conversion efficiency reaches 9.3%.

The invention discloses a method and device for automatically acquiring a thromboela-stogram. The device comprises a casing, a base and a lifting detection platform, wherein the lifting detection platform is mounted on the casing in a relative sliding manner through a guide rail, a driven turntable is mounted in the lifting detection platform, a liquid guide pipe penetrates through the circle center of the driven turntable to extend downwards, and is opposite to the circle center of a test tube, a detection pin is fixedly mounted on the driven turntable, and is positioned on one side of the liquid guide pipe, the tail end of the detection pin extends into the test tube, the test tube is arranged in a test tube cavity which is formed in a rotating platform, and the rotating platform is fixedly mounted in the base. According to the method and the device, the blood coagulation time, the full view of a blood coagulation process and the ablation time of blood clots under the action of each blood coagulation factor are obtained at one time for various places with a blood coagulation measurement requirement (before an operation/blood transfusion) at relative rotating speed, and the suppression effect of aspirin and thienopyridine medicaments on platelets can also be evaluated, so that the pain brought to a patient by collecting blood for many times is alleviated, and the detection efficiency is also improved.

The present invention relates to compounds which are 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides, their thieno-pyridone analogs, and prodrugs thereof. This invention specifically relates to such derivatives containing an N-hydrogen in the carboxanilide moiety and which exhibit modulating activity towards the aromatic hydrocarbon receptor (AhR), and, specifically, also to prodrugs thereof. The present invention also relates to use of said compounds as a medicament, and for the treatment of cancer, autoimmune disorders and other disorders with an immunological component, and a pharmaceutical composition comprising one or more of said compounds and a method of treatment.

The invention discloses an attapulgite based 3D printer bracket and a preparation method thereof. The preparation method comprises the following steps: (1) calcining attapulgite, shell and heilu soil, then putting a calcined object into a hydrochloric acid solution for acidizing, filtering and taking a filter cake, and then putting the filter cake to be under X-rays for activating treatment, thus obtaining an activated object; (2) mixing epoxy resin, phenol-furfural resin, methylcellulose, basic magnesium sulfate whisker, magnesium oxide, valine, glass fibre, pitch, sodium gualenate, aluminium potassium sulfate, thienopyridine, expansible graphite, ozocerite, sodium humate and coconut oil mono ethanol amide, fusing and cooling, thus obtaining the attapulgite based 3D printer bracket. The 3D printer bracket prepared by the method has excellent mechanical stability for improving the performance of a 3D printer.

The invention discloses a crystal form A of a compound 2-(4-(7-(2-fluoro-4-(1-((4-fluorophenyl) carbamoyl) cyclopropane-1-formamide) phenoxy) thieno [3, 2-b] pyridine-2-yl)-1H-pyrazolyl-1-yl) ethyl valine ester hydrochloride, a preparation method of the crystal form A and a pharmaceutical composition of the crystal form A. The crystal form is high in chemical stability, resistant to high temperature and high humidity, good in solubility and high in bioavailability, and the pharmaceutical composition of the crystal form has good dissolution rate and is suitable for development of preparations. The structural formula of the compound is shown as a formula (I),